Aryl Hydrocarbon Hydroxylases
"Aryl Hydrocarbon Hydroxylases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A large group of cytochrome P-450 (heme-thiolate) monooxygenases that complex with NAD(P)H-FLAVIN OXIDOREDUCTASE in numerous mixed-function oxidations of aromatic compounds. They catalyze hydroxylation of a broad spectrum of substrates and are important in the metabolism of steroids, drugs, and toxins such as PHENOBARBITAL, carcinogens, and insecticides.
Descriptor ID |
D001189
|
MeSH Number(s) |
D08.244.453.005 D08.811.682.690.708.170.010 D12.776.422.220.453.010
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aryl Hydrocarbon Hydroxylases".
Below are MeSH descriptors whose meaning is more specific than "Aryl Hydrocarbon Hydroxylases".
This graph shows the total number of publications written about "Aryl Hydrocarbon Hydroxylases" by people in this website by year, and whether "Aryl Hydrocarbon Hydroxylases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2004 | 1 | 0 | 1 |
2006 | 1 | 0 | 1 |
2009 | 0 | 1 | 1 |
2010 | 1 | 0 | 1 |
2011 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Aryl Hydrocarbon Hydroxylases" by people in Profiles.
-
Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clin Pharmacol Ther. 2014 Jun; 95(6):636-43.
-
Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus. Pharmacotherapy. 2011 Mar; 31(3):253-61.
-
Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing. Expert Rev Cardiovasc Ther. 2010 Mar; 8(3):339-43.
-
Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women. Breast Cancer Res. 2009; 11(4):R51.
-
A rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med. 2008 Feb; 10(2):89-98.
-
Interactions between CYP2C9 and UGT1A6 polymorphisms and nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Clin Gastroenterol Hepatol. 2006 Jul; 4(7):894-901.
-
CYP1A1 and CYP1B1 genotypes, haplotypes, and TCDD-induced gene expression in subjects from Seveso, Italy. Toxicology. 2005 Feb 14; 207(2):191-202.
-
Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2004 Jan; 13(1):94-101.